<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04390568</url>
  </required_header>
  <id_info>
    <org_study_id>1368-0043</org_study_id>
    <nct_id>NCT04390568</nct_id>
  </id_info>
  <brief_title>A Trial in Healthy Chinese Volunteers to Test How Different Doses of BI 655130 Are Taken up in the Body</brief_title>
  <official_title>An Open-label Phase I Trial to Assess Pharmacokinetics and Safety of Single Subcutaneous Doses and Single Intravenous Doses of BI 655130 in Healthy Chinese Male and Female Subjects (Single Doses, Open-label Study in Parallel-group Design).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this trial is to investigate pharmacokinetics, including dose&#xD;
      proportionality, following single intravenous and subcutaneous doses of spesolimab in healthy&#xD;
      Chinese subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 21, 2020</start_date>
  <completion_date type="Actual">June 4, 2021</completion_date>
  <primary_completion_date type="Actual">April 7, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC 0 to infinity of spesolimab</measure>
    <time_frame>Up to 179 days</time_frame>
    <description>Area under the concentration-time curve of spesolimab in plasma over the time interval from 0 extrapolated to infinity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of spesolimab</measure>
    <time_frame>Up to 179 days</time_frame>
    <description>Maximum measured concentration of spesolimab in plasma</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence of treatment-emergent adverse events (AEs)</measure>
    <time_frame>Up to 179 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of drug-related adverse events (AEs)</measure>
    <time_frame>Up to 179 days</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Dose group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose group 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose group 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 655130</intervention_name>
    <description>BI 655130</description>
    <arm_group_label>Dose group 1</arm_group_label>
    <arm_group_label>Dose group 2</arm_group_label>
    <arm_group_label>Dose group 3</arm_group_label>
    <arm_group_label>Dose group 4</arm_group_label>
    <arm_group_label>Dose group 5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male or female subjects (at least three subjects for each gender within each&#xD;
             dose group) according to the assessment of the investigator, as based on a complete&#xD;
             medical history including a physical examination, vital signs (blood pressure (BP),&#xD;
             pulse rate (PR), respiratory rate (RR), body temperature), 12-lead ECG, and clinical&#xD;
             laboratory tests.&#xD;
&#xD;
          -  Chinese ethnicity, according to the following criteria: Ethnic Chinese, born in China&#xD;
             and have 4 ethnic grandparents who were all born in China&#xD;
&#xD;
          -  Age of 18 to 45 years (inclusive)&#xD;
&#xD;
          -  Body weight ≥50 kg for male and ≥45 kg for female with body mass index (BMI) range ≥19&#xD;
             and &lt; 26 kg/m2 at visit 1&#xD;
&#xD;
          -  Signed and dated written informed consent prior to admission to the trial, in&#xD;
             accordance with GCP and local legislation&#xD;
&#xD;
          -  Female subjects who meet any of the following criteria from at least 30 days before&#xD;
             the first administration of trial medication until 16 weeks after trial completion&#xD;
             [c03320877-06]:&#xD;
&#xD;
               -  Women of childbearing potential (WOCBP)1 must be ready and able to use highly&#xD;
                  effective methods of birth control per ICH M3 (R2) that result in a low failure&#xD;
                  rate of less than 1% per year when used consistently and correctly. A list of&#xD;
                  contraception methods meeting these criteria is provided in the subject&#xD;
                  information&#xD;
&#xD;
               -  A vasectomised sexual partner (vasectomy at least one year prior to enrolment)&#xD;
&#xD;
               -  Surgically sterilised (including hysterectomy)&#xD;
&#xD;
               -  Postmenopausal, defined as at least one year of spontaneous amenorrhoea (in&#xD;
                  questionable cases a blood sample with simultaneous levels of&#xD;
                  follicle-stimulating hormone (FSH) above 40 U/L and estradiol below 30 mg/L is&#xD;
                  confirmatory)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Major surgery (major according to the investigator's assessment) performed within 12&#xD;
             weeks prior to treatment or planned within 12 months after screening, e.g. hip&#xD;
             replacement&#xD;
&#xD;
          -  Any finding in the medical examination (including BP, PR, RR, Body temperature or&#xD;
             12-lead ECG) deviating from normal and assessed as clinically relevant by the&#xD;
             investigator&#xD;
&#xD;
          -  Repeated measurement of systolic BP outside the range of 90 to 140 mmHg, diastolic BP&#xD;
             outside the range of 50 to 90 mmHg, or PR outside the range of 50 to 90 bpm&#xD;
&#xD;
          -  Any laboratory value outside the reference range that the investigator considers to be&#xD;
             of clinical relevance&#xD;
&#xD;
          -  Any evidence of a concomitant disease assessed as clinically relevant by the&#xD;
             investigator&#xD;
&#xD;
          -  Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,&#xD;
             immunological or hormonal disorders. Diseases of the central nervous system (including&#xD;
             but not limited to any kind of seizures or stroke), and other relevant neurological or&#xD;
             psychiatric disorders&#xD;
&#xD;
          -  History of relevant orthostatic hypotension, fainting spells, or blackouts&#xD;
&#xD;
          -  Chronic or relevant acute infections including active and latent tuberculosis, human&#xD;
             immunodeficiency virus (HIV) or viral hepatitis; QuantiFERON tuberculosis (TB) test&#xD;
             will be performed at screening Further exclusion criteria apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Huashan Hospital, Fudan University</name>
      <address>
        <city>Shanghai</city>
        <zip>200040</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>https://www.mystudywindow.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 13, 2020</study_first_submitted>
  <study_first_submitted_qc>May 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 15, 2020</study_first_posted>
  <last_update_submitted>June 15, 2021</last_update_submitted>
  <last_update_submitted_qc>June 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents, except for the following exclusions:&#xD;
studies in products where Boehringer Ingelheim is not the license holder;&#xD;
studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials;&#xD;
studies conducted in a single center or targeting rare diseases (because of limitations with anonymization).&#xD;
For more details refer to: https://www.mystudywindow.com/msw/datasharing</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

